Breaking Down Zhejiang Juhua Co., Ltd. Financial Health: Key Insights for Investors

Zhejiang Juhua's recent results demand attention: revenue for the first nine months of 2025 reached ¥20.39 billion (+13.8% YoY) as higher refrigerant prices lifted top-line performance, while net profit (H1) was reported between ¥1.97-2.13 billion (up 136-155% YoY) and Q2 net profit hit ¥1.161-1.321 billion (a QoQ jump of 43.5-63.3% from Q1's ¥809 million); profitability metrics are striking-TTM net margin 14.69%, operating margin 18.28%, ROA 6.73% and ROE 14.57%-supported by an expanded gross margin of 33%, a conservative debt/equity ratio of 21.25%, total assets of ¥34.25 billion (+20.1% YoY), strong liquidity with operating cash flow of ¥3.63 billion (+361.5% YoY) and cash equivalents of ¥4.053 billion (+188.79% YoY), and market metrics including market cap CN¥78.24 billion, enterprise value CN¥95.11 billion, trailing P/E 23.03, forward P/E 21.18, P/S 3.41 and P/B 4.00; growth levers include projected pharmaceutical exports of ¥2.5 billion by 2025 and an ¥800 million wind-farm investment expected to contribute 10-15% of profits by 2026, while risks span subsidy phaseouts, commodity volatility, regulatory shifts, geopolitical tensions and intensifying competition-dig into the full analysis for detailed implications for investors

Zhejiang Juhua Co., Ltd. (600160.SS) - Revenue Analysis

• First 9 months 2025 revenue: ¥20.39 billion (+13.8% YoY)
• Primary driver: higher refrigerant product prices (price mix contribution)
• Improved gross margin due to both higher sales and favorable pricing

• Price-led revenue growth: the refrigerant product price uptick was the principal catalyst for the 13.8% revenue increase.
• Strong sequential profit improvement: Q2 net profit (¥1.161-¥1.321B) rose substantially from Q1's ¥809M, signaling margin recovery.
• Balance sheet expansion: total assets reached ¥34.25B, up 20.1% year-over-year, supporting scale and working-capital needs.

Zhejiang Juhua Co., Ltd. (600160.SS) - Profitability Metrics

• Net income (Q3 2025): ¥1.20 billion vs ¥417.8 million in Q3 2024 - ~187% year-over-year increase.
• Net profit margin (TTM): 14.69%.
• Operating margin: 18.28%, indicating efficient cost management of operations.
• Return on assets (TTM): 6.73%.
• Return on equity (TTM): 14.57%.
• Gross margin: 33% (expanded from 30% in 2020); net margins reached 17% in 2022 - both above industry benchmarks.

• Implications: Elevated gross and operating margins signal pricing power and cost discipline; ROE near 15% aligns with attractive shareholder returns given moderate asset base (ROA 6.73%).
• Risk considerations: Sustaining higher margins depends on raw material cost trends, end-market demand, and continued operational efficiency.

Zhejiang Juhua Co., Ltd. (600160.SS) - Debt vs. Equity Structure

• Leverage posture: A 21.25% debt-to-equity ratio underscores reliance on equity financing and relatively low financial risk from debt service.
• Valuation context: EV/CAP shows debt adds roughly CN¥16.87 billion to market cap (EV - Market Cap), signaling modest net debt exposure embedded in enterprise value.
• Earnings multiples: Trailing P/E 23.03 vs forward P/E 21.18 implies expected earnings growth or margin improvement priced in by the market.
• Investor sentiment: P/S of 3.41 and P/B of 4.00 reflect confidence in revenue growth and intangible value beyond book equity.
• Balance sheet expansion: Total assets rising 20.1% year-over-year to ¥34.25 billion suggests active reinvestment or acquisition activity supporting growth.

• A conservative debt ratio provides flexibility for capex or M&A without materially increasing financial stress.
• Moderate P/E multiples place the company in a range where execution on growth and margin targets will drive valuation upside or downside.
• Elevated P/B signals that investors are paying for intangible growth drivers-management must sustain ROE to justify the premium.

Zhejiang Juhua Co., Ltd. (600160.SS) - Liquidity and Solvency

Key liquidity and solvency indicators point to a markedly strengthened short-term cash position and manageable leverage as of the latest quarter.

• Net cash flow from operating activities: ¥3.63 billion (↑361.5% YoY).
• Cash and cash equivalents: ¥4.053 billion (↑188.79% YoY).
• Total assets at quarter-end: ¥34.25 billion (↑20.1% YoY).
• Current and quick ratios: not disclosed explicitly, but inferred to be healthy given high cash reserves and limited reported debt.
• Debt-to-equity: described as low, indicating manageable long-term leverage.

Practical implications for investors:

• Strong operating cash flow and cash balances reduce short-term refinancing risk and increase capacity for capex, dividends, or opportunistic buybacks.
• Asset growth of 20.1% supports scale expansion but warrants monitoring for asset quality and return on assets.
• Absence of explicit current/quick ratios and total liabilities requires investors to review detailed balance-sheet disclosures and notes for complete solvency assessment.

For broader context on the company's strategy, history and ownership structure see: Zhejiang Juhua Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Zhejiang Juhua Co., Ltd. (600160.SS) - Valuation Analysis

• Trailing P/E: 23.03
• Forward P/E: 21.18
• Price-to-Sales (P/S): 3.41
• Price-to-Book (P/B): 4.00
• Enterprise Value (EV): CN¥95.11 billion
• Market Capitalization (as of July 1, 2025): CN¥78.24 billion
• Total assets at quarter-end: ¥34.25 billion (up 20.1% YoY)

• Valuation dynamics: EV-to-market-cap gap (EV CN¥95.11B vs. Market Cap CN¥78.24B) reflects net debt and minority interests - useful when comparing to peers on EV/EBITDA.
• Earnings multiple context: Forward P/E of 21.18 vs. trailing 23.03 implies expected earnings growth or margin improvement priced in by the market.
• Balance-sheet signal: P/B at 4.00 and assets up 20.1% year-over-year indicate investor willingness to pay for growth off the balance sheet, but also a reduced margin for asset write-downs.
• Revenue leverage: P/S 3.41 suggests investors expect above-average revenue conversion to profits relative to lower-P/S peers.

Zhejiang Juhua Co., Ltd. (600160.SS) - Risk Factors

• Phaseout of renewable energy subsidies: Zhejiang Juhua's growing exposure to renewable-energy-linked revenues (notably through joint ventures and project investments) faces sensitivity to China's subsidy retrenchment.
• Commodity-price volatility: Raw materials such as caustic soda, chlorine derivatives and specialty feedstocks drive input cost exposure and margin swings.
• Regulatory shifts: Changes in pharmaceutical, chemical environmental standards, and renewable energy policy can increase compliance costs or constrain product approvals.
• Geopolitical tensions: Export markets and cross-border supply chains may be disrupted by tariffs, sanctions, or shipping constraints.
• Competitive pressure: Intensifying competition from domestic large-scale chemical producers and international specialty-chemical firms can compress pricing and market share.
• Operational/project execution risks: Large-scale renewable projects (e.g., wind farms) introduce technological, construction, and commissioning risks that may delay revenue realization or require extra capital.

• Quantifying subsidy-phaseout risk: If feed-in or project subsidies decline by 30-50% relative to prior levels, modeled EBITDA contribution from renewable projects could fall by an estimated 15-25% through reduced IRR and slower new-project rollouts.
• Commodity sensitivity example: A 10% uptick in core feedstock prices (caustic/chlor-alkali chain) can compress gross margins by ~2-4 percentage points, based on historical cost pass-through limitations.
• Regulatory event scenarios: Stricter environmental standards could trigger incremental compliance capex of several hundred million RMB over 2-3 years in a high-impact scenario.
• Geopolitical/supply-chain shocks: Disruptions could increase lead times and logistics costs; a regional export slowdown of 20% could reduce segment revenue proportionally in affected product lines.
• Competitive dynamics: Market share erosion risk concentrated in commodity chemicals; specialty and pharma segments offer differentiation but require sustained R&D and quality control spending.
• Project execution: Large wind and energy-storage projects carry timeline slip and cost-overrun risks; a single major delay could push back revenue recognition by 6-18 months and necessitate additional financing.

• Mitigation levers the company can deploy:
• Hedging strategies and long-term supply contracts to manage raw-material price swings.
• Portfolio tilt toward higher-margin specialty chemicals and pharmaceutical intermediates to reduce commodity sensitivity.
• Conservative project staging and stronger EPC oversight to limit renewable-project execution risk.
• Active monitoring of regulatory developments and preemptive compliance investments to avoid sudden operational disruptions.

Zhejiang Juhua Co., Ltd. (600160.SS) - Growth Opportunities

• Pharmaceutical exports: projected to reach ¥2.5 billion by 2025, driven by global demand for affordable generics and expanding international distribution channels.
• Renewable energy investment: an ¥800 million capital allocation to a wind farm intended to support China's 2060 carbon neutrality goals; management expects the wind farm to contribute roughly 10-15% of company profits by 2026.
• Operational efficiency: gross margin expanded to 33% (from 30% in 2020), indicating cost control and product-mix improvements.
• Profitability: net profit margin reached 17% in 2022, outperforming many peers and underscoring strong bottom-line performance.
• Balance-sheet growth: total assets at quarter-end were ¥34.25 billion, a 20.1% increase from the previous year-end, signaling capacity for further investment and scale.

• Revenue trend note: total revenue fell from 7,531.08 in the previous quarter to 7,062.36 in the latest quarter - monitoring seasonality, product mix, and FX exposure is important for near-term outlook.
• Investment implications: the ¥800 million wind farm both diversifies revenue and aligns with ESG tailwinds, potentially unlocking new investor pools and long-term margin enhancement.
• Scale and reinvestment: a ¥34.25 billion asset base (+20.1% YoY) provides room for continued capex in manufacturing and international expansion of pharmaceutical sales.